


**Amendments to the Claims:**

Please amend claims 42-45 as shown in the listing of claims. This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-24. (Canceled)

25. (Previously Presented) A compound according to the formula IA:



IA

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof,  
wherein

D is absent or selected from the group consisting of

- (1) substituted or unsubstituted C<sub>3</sub>-C<sub>8</sub>-cycloalkyl;
- (2) substituted or unsubstituted aryl;
- (3) substituted or unsubstituted heterocyclyl; and
- (4) substituted or unsubstituted heteroaryl;

Y is selected from the group consisting of

- (1) substituted or unsubstituted C<sub>3</sub>-C<sub>8</sub>-cycloalkyl;
- (2) substituted or unsubstituted aryl;
- (3) substituted or unsubstituted heterocyclyl; and
- (4) substituted or unsubstituted heteroaryl;

R<sub>4</sub> is H or substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl;

A is selected from the group consisting of

(1)  $-\text{C}(\text{R}^{1a}, \text{R}^{2a})\text{OR}^{3a}$ ; and

(2)  $-\text{C}(\text{R}^{1a}, \text{R}^{2a})\text{N}(\text{R}^{4a}, \text{R}^{5a})$ ;

wherein  $\text{R}^{1a}$ ,  $\text{R}^{2a}$ ,  $\text{R}^{3a}$ ,  $\text{R}^{4a}$ , and  $\text{R}^{5a}$  are independently selected from the group consisting of

(1) H; and

(2) substituted and unsubstituted  $\text{C}_1$ - $\text{C}_6$ -alkyl.

26. (Previously Presented) The compound of claim 25, wherein A is  $-\text{C}(\text{R}^{1a}, \text{R}^{2a})\text{OR}^{3a}$ .

27. (Previously Presented) The compound of claim 26, wherein A is  $-\text{CH}_2\text{OH}$ .

28. (Previously Presented) The compound of claim 26, wherein A is  $-\text{CH}(\text{CH}_3)\text{OH}$ .

29. (Previously Presented) The compound of claim 25, wherein A is  $-\text{C}(\text{R}^{1a}, \text{R}^{2a})\text{N}(\text{R}^{4a}, \text{R}^{5a})$ .


30. (Previously Presented) The compound of claim 29, wherein A is  $-\text{CH}_2\text{NH}_2$ .

31. (Previously Presented) The compound of claim 29, wherein A is  $-\text{CH}(\text{CH}_3)\text{NH}_2$ .

32. (Previously Presented) The compound of claim 25, wherein D is absent and Y is a substituted or unsubstituted aryl.

33. (Previously Presented) The compound of claim 25, wherein D is a substituted or unsubstituted aryl and Y is a substituted or unsubstituted aryl.

34. (Currently Amended) A compound according to the formula IB:



IB

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof,

wherein

D is absent or selected from the group consisting of

- (1) substituted or unsubstituted C<sub>3</sub>-C<sub>8</sub>-cycloalkyl;
- (2) substituted or unsubstituted aryl;
- (3) substituted or unsubstituted heterocyclyl; and
- (4) substituted or unsubstituted heteroaryl;

G is ~~absent or~~ is -C≡C-C≡C-;

Y is selected from the group consisting of

- (1) substituted or unsubstituted C<sub>3</sub>-C<sub>8</sub>-cycloalkyl;
- (2) substituted or unsubstituted aryl;
- (3) substituted or unsubstituted heterocyclyl; and
- (4) substituted or unsubstituted heteroaryl;

R<sub>4</sub> is H or substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl;

A is ~~selected from the group consisting of~~

~~(1) -C(R<sup>1a</sup>, R<sup>2a</sup>)OR<sup>3a</sup>; and~~

~~(2) -C(R<sup>1a</sup>, R<sup>2a</sup>)N(R<sup>4a</sup>, R<sup>5a</sup>);~~


wherein R<sup>1a</sup>, R<sup>2a</sup>, R<sup>3a</sup>, R<sup>4a</sup>, and R<sup>5a</sup> are independently selected

from the group consisting of

- (1) H; and
- (2) substituted and unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl.

35. (Currently Amended) A compound ~~of claim 34~~ according to Formula

VIII:



VIII

or stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof, wherein

E is absent or selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl,
- (3) substituted or unsubstituted aryl,
- (4) substituted or unsubstituted heterocyclyl, and
- (5) substituted or unsubstituted heteroaryl,


or E and R<sup>3L</sup>, together with the atoms to which they are attached form a substituted or unsubstituted heterocyclic ring, having from 5 to 10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring system are selected from N, O and S;

R<sup>1L</sup>, R<sup>3L</sup> are independently selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl,
- (3) C<sub>1</sub>-C<sub>6</sub>-alkyl substituted with aryl,
- (4) C<sub>1</sub>-C<sub>6</sub>-alkyl substituted with heterocyclyl, and
- (5) C<sub>1</sub>-C<sub>6</sub>-alkyl substituted with heteroaryl,

or R<sup>1L</sup> and R<sup>3L</sup>, together with the atoms to which they are attached form a substituted or unsubstituted heterocyclic ring, having from 5 to 7 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S.

36. (Previously Presented) A compound of claim 34 according to Formula IX:



IX

or stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof, wherein

E is absent or selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl,
- (3) substituted or unsubstituted aryl,
- (4) substituted or unsubstituted heterocyclyl, and
- (5) substituted or unsubstituted heteroaryl,


or E and R<sup>3L</sup>, together with the atoms to which they are attached form a substituted or unsubstituted heterocyclic ring, having from 5 to 10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring system are selected from N, O and S;

R<sup>1L</sup>, R<sup>3L</sup> are independently selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl,
- (3) C<sub>1</sub>-C<sub>6</sub>-alkyl substituted with aryl,
- (4) C<sub>1</sub>-C<sub>6</sub>-alkyl substituted with heterocyclyl, and
- (5) C<sub>1</sub>-C<sub>6</sub>-alkyl substituted with heteroaryl,

or R<sup>1L</sup> and R<sup>3L</sup>, together with the atoms to which they are attached form a substituted or unsubstituted heterocyclic ring, having from 5 to 7 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S.

37. (Previously Presented) A compound of claim 34 according to Formula X:



X

or stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof, wherein E is absent or selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl,
- (3) substituted or unsubstituted aryl,
- (4) substituted or unsubstituted heterocyclyl, and
- (5) substituted or unsubstituted heteroaryl,

or E and R<sup>3L</sup>, together with the atoms to which they are attached form a substituted or unsubstituted heterocyclic ring, having from 5 to 10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring system are selected from N, O and S;

R<sup>1L</sup>, R<sup>3L</sup> are independently selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl,
- (3) C<sub>1</sub>-C<sub>6</sub>-alkyl substituted with aryl,
- (4) C<sub>1</sub>-C<sub>6</sub>-alkyl substituted with heterocyclyl, and
- (5) C<sub>1</sub>-C<sub>6</sub>-alkyl substituted with heteroaryl,

or R<sup>1L</sup> and R<sup>3L</sup>, together with the atoms to which they are attached form a substituted or unsubstituted heterocyclic ring, having from 5 to 7 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S.

38. (Previously Presented) A pharmaceutical composition comprising the compound of claim 25 and a pharmaceutically acceptable excipient.

39. (Previously Presented) A pharmaceutical composition comprising the compound of claim 34 and a pharmaceutically acceptable excipient.

40. (Previously Presented) A pharmaceutical composition comprising a compound of claim 25, a second agent, and a pharmaceutically acceptable excipient, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

41. (Previously Presented) A pharmaceutical composition comprising a compound of claim 34, a second agent, and a pharmaceutically acceptable excipient, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

42. (Currently Amended) A method of inhibiting LpxC~~treating a patient~~ comprising administering to a patient in need thereof, an effective amount of the compound of claim 25.

43. (Currently Amended) A method of inhibiting LpxC~~treating a patient~~ comprising administering to a patient in need thereof, an effective amount of the compound of claim 34.

44. (Currently Amended) A method of inhibiting LpxC~~treating patient~~ comprising administering to a patient in need thereof, an effective amount of the compound of claim 25 and an effective amount of a second agent, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

45. (Currently Amended) A method of inhibiting LpxC~~treating patient~~ comprising administering to a patient in need thereof, an effective amount of the compound of claim 34 and an effective amount of a second agent, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

46. (Previously Presented) A method of treating an infection comprising administering to a patient in need thereof, an effective amount of the compound of claim 25.

47. (Previously Presented) A method of treating an infection comprising administering to a patient in need thereof, an effective amount of the compound of claim 34.

48. (Previously Presented) A method of treating an infection comprising administering to a patient in need thereof, an effective amount of the compound of claim 25 and an effective amount of a second agent, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

49. (Previously Presented) A method of treating an infection comprising administering to a patient in need thereof, an effective amount of the compound of claim 34 and an effective amount of a second agent, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.